Oral Celecoxib and Ciprofloxacin Slow Functional Decline in ALS
A phase 2b trial shows the fixed-dose combination is safe and reduces the risk of severe complications over 18 months in early-stage ALS.
Apps for Alcohol Use Do Not Improve Mood Beyond Standard Care
In a randomized trial, digital tools added to standard care did not further reduce depression or anxiety in adults with alcohol dependence.
Tumor Debulking Adds Toxicity Without Survival Benefit in Metastatic Colorectal Cancer
Adding tumor debulking to chemotherapy fails to extend survival and increases severe adverse events in metastatic colorectal cancer.
Limiting ICU Wrist Restraints Fails to Increase Delirium-Free Days
A restrictive wrist-strap protocol in mechanically ventilated adults did not improve delirium-free days or increase self-extubation risk.
12-Week Diet and Exercise Program Improves Post-ICU Physical Function
A 12-week regimen of exercise and protein supplementation significantly improves physical functioning in long-stay ICU survivors.
High-Flow Oxygen Lowers Intubation but Does Not Improve Survival
High-flow nasal cannula therapy reduces intubation rates in acute hypoxemic respiratory failure without altering 28-day mortality.
Prehospital Whole Blood Shows No Survival Benefit Over Component Therapy
A randomized trial of 616 trauma patients found prehospital whole blood did not reduce 24-hour mortality or massive transfusion needs.
Web-Based School Program Reduces New-Onset Mental Health Problems
An eight-session internet intervention focused on stress management lowered the one-year incidence of mental health issues from 28% to 21%.
Community Care for HIV, HTN, Diabetes Matches Clinic-Based Model
A trial in Tanzania and Uganda found non-inferior HIV suppression and comparable cardiometabolic control in a community-based model.
Women Face Worse Functional Recovery After Intensive Care EEG
Despite similar acute management and mortality, critically ill women are half as likely as men to achieve favorable long-term recovery.
Decision Tool Reduces Antidepressant Discontinuation in Depression
A web-based system personalizing antidepressant selection kept more patients on therapy at 8 weeks and improved symptoms at 24 weeks.
Obinutuzumab Shows High Efficacy in Active Systemic Lupus Erythematosus
A phase 3 trial shows the anti-CD20 antibody obinutuzumab significantly improves clinical responses and reduces flares in active lupus.